These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 34537483)

  • 21. Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell carcinoma.
    Bila M; Franken A; Van Dessel J; Garip M; Meulemans J; Willaert R; Hoeben A; Vander Poorten V; Clement PM
    Oral Oncol; 2024 Feb; 149():106664. PubMed ID: 38113661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
    Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
    Front Immunol; 2021; 12():652054. PubMed ID: 34305889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
    Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
    J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.
    Lee PC; Chao Y; Chen MH; Lan KH; Lee IC; Hou MC; Huang YH
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32863270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
    Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
    Iacovelli R; Ciccarese C; Bria E; Bracarda S; Porta C; Procopio G; Tortora G
    Eur J Cancer; 2020 Sep; 136():195-203. PubMed ID: 32712550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging immune checkpoint inhibitors for the treatment of head and neck cancers.
    Green SE; McCusker MG; Mehra R
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):501-514. PubMed ID: 33196319
    [No Abstract]   [Full Text] [Related]  

  • 28. Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis.
    Park R; Lopes L; Saeed A
    Clin Transl Oncol; 2021 Jan; 23(1):100-109. PubMed ID: 32495269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of immune checkpoint inhibitors differs in various status of carcinoma: a study based on 29 cohorts with 3255 participants.
    Wu C; Ke Y; Wan L; Xie X
    Cancer Immunol Immunother; 2024 Mar; 73(5):79. PubMed ID: 38554165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The research progress of PD-1/L1 inhibitors application in the treatment of head and neck squamous cell carcinoma].
    Song P; Yan X; Jiang Y; Ye Y; Wang J; Han P
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2022 Apr; 36(4):315-320. PubMed ID: 35511629
    [No Abstract]   [Full Text] [Related]  

  • 31. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An Immune-Related Gene Prognostic Index for Head and Neck Squamous Cell Carcinoma.
    Chen Y; Li ZY; Zhou GQ; Sun Y
    Clin Cancer Res; 2021 Jan; 27(1):330-341. PubMed ID: 33097495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The predictive and prognostic value of weight loss and body composition prior to and during immune checkpoint inhibition in recurrent or metastatic head and neck cancer patients.
    Willemsen ACH; De Moor N; Van Dessel J; Baijens LWJ; Bila M; Hauben E; van den Hout MFCM; Vander Poorten V; Hoeben A; Clement PM; Schols AMWJ
    Cancer Med; 2023 Apr; 12(7):7699-7712. PubMed ID: 36484469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.
    Ding Z; Dong Z; Chen Z; Hong J; Yan L; Li H; Yao S; Yan Y; Yang Y; Yang C; Li T
    Front Immunol; 2021; 12():733530. PubMed ID: 34659220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The primary site of head and neck squamous cell carcinoma predicts survival benefits of EGFR inhibitors: A systematic review and meta-analysis.
    Nie D; Wang X; Sun M; Feng Z; Pei F; Liu W; Wang Z; Han F
    Radiother Oncol; 2021 May; 158():13-20. PubMed ID: 33587969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings.
    Boschert V; Teusch J; Aljasem A; Schmucker P; Klenk N; Straub A; Bittrich M; Seher A; Linz C; Müller-Richter UDA; Hartmann S
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020).
    Haber PK; Puigvehí M; Castet F; Lourdusamy V; Montal R; Tabrizian P; Buckstein M; Kim E; Villanueva A; Schwartz M; Llovet JM
    Gastroenterology; 2021 Sep; 161(3):879-898. PubMed ID: 34126063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A systematic review of neoadjuvant and definitive immunotherapy in locally advanced head and neck squamous cell carcinoma.
    Nindra U; Hurwitz J; Forstner D; Chin V; Gallagher R; Liu J
    Cancer Med; 2023 May; 12(10):11234-11247. PubMed ID: 36934434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current landscape of immunotherapy trials in locally advanced and high-risk head and neck cancer.
    Park R; Park JC
    Immunotherapy; 2021 Aug; 13(11):931-940. PubMed ID: 34100301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-1/PD-L1 inhibitor monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a meta-analysis.
    Chen L; Mo DC; Hu M; Zhao SJ; Yang QW; Huang ZL
    Am J Otolaryngol; 2022; 43(2):103324. PubMed ID: 34923281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.